Product Description
Bone morphogenetic protein-2 (BMP-2) is currently the only Food and Drug Administration (FDA)-approved osteoinductive growth factor used as a bone graft substitute. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964756/)
Mechanisms of Action: Bone formation Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral,Percutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Daewoong
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Other
Phase 2: Periodontitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ChiCTR2400095016 | N/A |
Not yet recruiting |
Tuberculosis, Spinal |
2028-12-31 |
|||
| novel biomarkers and ISR | N/A |
Not yet recruiting |
Coronary Restenosis |
2025-01-01 |
2023-11-29 |
Primary Endpoints|Treatments |
|
| JapicCTI-205101 | P2 |
Unknown |
Unknown |
2022-05-31 |
|||
| ChiCTR2100047693 | N/A |
Completed |
Neuromyelitis Optica|Lyme Disease|Surgical Wound Infection|Osteoporosis|Transplantation Unspecified |
2021-06-16 |
|||
| NF107-BMP2 | N/A |
Terminated |
Neurofibromatosis 1|Pseudarthrosis|Neurofibromatoses |
2020-06-01 |
50% |
2021-10-28 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| SVSIDS/PERIO/4/2017 | P2 |
Completed |
Periodontitis |
2019-09-20 |
2020-05-01 |
Primary Endpoints|Treatments |
|
| SCNONUNION12 | P1 |
Unknown status |
Other |
2014-12-01 |
2019-03-19 |
Treatments |
|
| BA05-CP01 | P3 |
Completed |
Other |
2012-06-01 |
2019-03-19 |
Treatments |